Genes (25)
Species: human : 25 | |
Human | PROM2 | 150696 | prominin 2 | The PROM2 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | MAL2 | 114569 | mal, T-cell differentiation protein 2 (gene/pseudogene) | The MAL2 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | ESRP1 | 54845 | epithelial splicing regulatory protein 1 | The FLJ20171 gene was shown to effectively separate these two chromophobe renal cell carcinoma (RCC) and benign oncocytoma groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | NDUFA13 | 51079 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 | No GRIM-19 mutations were detected in any of the six cases of known familial Hurthle cell tumour tested, so that our results do not support the identification of GRIM-19 as the TCO gene. The GRIM-19 mutations we have detected are the first nuclear gene mutations specific to Hurthle cell tumours to be reported to date; we propose that such mutations can be involved in the genesis of sporadic or familial Hurthle cell tumours through the dual function of GRIM-19 in mitochondrial metabolism and cell death.British Journal of Cancer (2005) 92, 1892-1898. | Human | ANKRD2 | 26287 | ankyrin repeat domain 2 (stretch responsive muscle) | ARPP was localized in mitochondria and nuclei in both the normal distal renal tubule and oncocytoma but not in chromophobe renal cell carcinomas | Human | PPRC1 | 23082 | peroxisome proliferator-activated receptor gamma, coactivator-related 1 | overexpression of the PRC pathway is responsible for mitochondrial proliferation in the context of thyroid oncocytoma | Human | AP1M2 | 10053 | adaptor-related protein complex 1, mu 2 subunit | The AP1M2 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | CLDN8 | 9073 | claudin 8 | claudin-7 and claudin-8 have potential use as immunohistochemical biomarkers in the differential diagnosis of chromophobe renal cell carcinoma and oncocytoma | Human | NCOA4 | 8031 | nuclear receptor coactivator 4 | RET hybrid oncogenes (7x RET/PTC1, 1x RET/PTC1L, 2x RET/PTC3, 5 uncharacterized RET/PTCx) were demonstrated in 7 of 27 HCCs, in 0 of 4 oxyphilic FTCs, in 4 of 5 oxyphilic PTCs, in 1 of 2 HCC-UTCs, and in 3 of 16 oxyphilic adenomas. | Human | TPO | 7173 | thyroid peroxidase | Remarkably, oncocytic cells from both Hashimoto;s thyroiditis and oncocytic adenoma, typically packed with mitochondria, displayed evident TPO reaction exclusively in mitochondrial cristae. | Human | SYP | 6855 | synaptophysin | Immunohistochemical analyses using antibodies against the major pituitary hormones, the alpha-subunit of glycoprotein hormones, chromogranin and synaptophysin were performed on 10 adenomas with oncocytic parts (26%-50% oncocytes, Group I), on 9 oncocytic adenomas with 51%-75% oncocytes (Group II), and on 12 oncocytic adenomas with 76%-100% oncocytes (Group III). | Human | S100A1 | 6271 | S100 calcium binding protein A1 | S100A1 was expressed in 2/15 clear cell RCCs, 11/15 papillary RCCs, 7/8 oncocytomas and in 0/7 chromophobe RCCs S100A1 immunodetection is potentially useful for the differential diagnosis between chromophobe renal cell carcinoma and oncocytoma | Human | PXN | 5829 | paxillin | expression in conventional renal cell carcinomas (RCCs), papillary RCCs, chromophobe RCCs, collecting duct carcinomas, oncocytomas; role in signal transductions as a focal adhesion between tumor cells and the ECM in tumors with collecting duct phenotypes | Human | PRSS8 | 5652 | protease, serine, 8 | The PRSS8 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | PAX2 | 5076 | paired box 2 | potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma from chromophobe RCC, (ii) clear cell RCC and papillary RCC from renal tumors with Xp11.2 translocation and (iii) high-grade clear cell RCC from urothelial carcinoma | Human | MST1R | 4486 | macrophage stimulating 1 receptor (c-met-related tyrosine kinase) | immunostaining and Western blot showed Ron in normal kidney and in all oncocytomas but never in renal cell carcinomas or in the renal carcinoma cell line Caki-1; Ron was expressed in phosphorylated, i.e., active, form | Human | NR3C2 | 4306 | nuclear receptor subfamily 3, group C, member 2 | Our study indicates MR and 11beta-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (chromophobe renal cell carcinomas and oncocytomas) | Human | MIF | 4282 | macrophage migration inhibitory factor (glycosylation-inhibiting factor) | Macrophage migration inhibitory factor was found in 3 of 4 thyrotroph adenomas, 3 of 6 gonadotroph adenomas, 10 of 11 functioning corticotroph and 8 of 10 silent corticotroph adenomas, 3 of 3 null cell adenomas, and 3 of 3 oncocytic adenomas. | Human | KITLG | 4254 | KIT ligand | KIT expression is a hallmark of oncocytoma and chromophobe renal cell carcinoma | Human | KIT | 3815 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | KIT gene was expressed in 6/7 chromophobe RCCs and 7/8 oncocytomas while 0/15 clear cell RCCs and 1/15 papillary RCCs expressed kit gene found a significant elevation of c-kit protein messenger RNA and protein overexpression not only in chromophobe renal cell carcinomas but also in oncocytomas | Human | DRD2 | 1813 | dopamine receptor D2 | By ISH, a variable D2R signal was detected in 79 of 89 cases: 4 of 6 densely granulated and 8 of 8 sparsely granulated somatotroph, 4 of 4 mammosomatotroph, 7 of 7 mixed somatotroph-lactotroph, 4 of 4 acidophil stem cell, 16 of 16 sparsely granulated lactotroph, 11 of 16 corticotroph (functioning and silent), 3 of 4 silent subtype 3, 5 of 5 thyrotroph, 5 of 6 gonadotroph, 5 of 6 null cell, and 7 of 7 oncocytic adenomas. | Human | CLDN7 | 1366 | claudin 7 | claudin-7 and claudin-8 have potential use as immunohistochemical biomarkers in the differential diagnosis of chromophobe renal cell carcinoma and oncocytoma Claudin-7 to be a candidate expression marker for distinguishing chromophobe renal cell carcinoma from other renal tumor subtypes, including the morphologically similar oncocytoma | Human | TNFSF8 | 944 | tumor necrosis factor (ligand) superfamily, member 8 | In another oncocytic adenoma, another 4 conventional PTC and another 7 non-conventional PTC CD30L/CD30 expression was associated to expression of IL-6 only. Co-expression of IL-6 and IL-6R in the epithelial (follicular) cells was observed solely in CD30L/CD30 positive nodules: 5/15 (33%) oncocytic adenomas; 6/30 (20%) follicular adenomas which belonged to 2 variants (4/4 microfollicular toxic and 2/2 hyalinizing trabecular); 9/30 (30%) papillary thyroid cancers (PTC), all belonging to the conventional variant. IL-6 staining associated to absent expression of CD30L and CD30 was observed in 7 follicular adenomas (all belonging to variants different from toxic and hyalinizing trabecular), 2 oncocytic adenomas, 5 of the 30 colloid nodules and 2 normal thyroids. | Human | CAV1 | 857 | caveolin 1, caveolae protein, 22kDa | A statistically significant difference in the expression of caveolin-1 between oncocytoma with a mean labeling index of 91.7 and other malignant renal tumors with a lower mean labeling index possibly implicates this peptide in oncocytoma pathogenesis | Human | BRAF | 673 | v-raf murine sarcoma viral oncogene homolog B | In this study, we analyzed 320 thyroid tumors and six anaplastic carcinoma cell lines and detected BRAF mutations in 45 (38%) papillary carcinomas, two (13%) poorly-differentiated carcinomas, three (10%) anaplastic carcinomas, and five (83%) thyroid anaplastic carcinoma cell lines but not in follicular, Hurthle cell, and medullary carcinomas, follicular and Hurthle cell adenomas, or benign hyperplastic nodules. |
|